The trial, part of the federal government’s Operation Warp Speed, will include at least 1,000 people and is set to begin July 9. At least 400 people will be 65 or older, and researchers are hoping to test a large number of African American and Latino residents, both groups that are at a high risk of infection and death. They’re also hoping to test people working in warehouses and manufacturing sites, places with high risk of the virus spreading.
Researchers aim to determine if the vaccine is effective in preventing COVID-19 and severe COVID-19 illness, according to the Sun-Times.
The trial is scheduled to last two years, but researchers said that if the vaccine proves to be effective by the end of this year or in early next year, it could be approved for use in 2021.
Study participants will be given a shot at the beginning of the trial and another a month later, with half receiving the vaccine and half receiving a placebo.
UIC is one of several sites in the U.S. that will test Moderena’s vaccine, and more than 30,000 people are expected to enroll in the trials, the Sun-Times reported.
Read the full article here.
More articles on pharmacy:
FDA rescinds hydroxychloroquine emergency use authorization
6 recent drug, device recalls
10 exec moves affecting the pharma industry
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
